AEterna Zentaris (NASDAQ:AEZS) was upgraded from Hold to Buy at MLV Equity today. The stock closed yesterday at $2.55 on volume of 2.2 million shares, above average daily volume of 691,000.

AEterna Zentaris Inc is a biopharmaceutical company focused in oncology and endocrine therapy. The Company's portfolio includes an orally-active inhibitor for multiple cancers, as well a product marketed for in vitro fertilization. AEterna Zentaris also develops and sells active ingredients, specialty chemicals, cosmetic, and nutritional products.

AEterna Zentaris has overhead space with shares priced $2.54, or 46.5% below the average consensus analyst price target of $4.75. AEterna Zentaris shares have support at the 50-day moving average (MA) of $2.20 and additional support at the 200-day MA of $1.14.

Over the past year, AEterna Zentaris has traded in a range of $0.38 to $3.55 and closed yesterday at $2.54, 568% above that low. The 200-day and 50-day moving averages have moved 0.95% higher and 0.23% higher over the past week, respectively.

SmarTrend is monitoring the recent change of momentum in AEterna Zentaris. Please refer to our Company Overview for the results of our proprietary technical indicators that have been scanning shares of AEterna Zentaris in search of a potential trend change.